🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Exciting News: We’re proud to share that our bispecific antibody has been approved in China for the treatment of adults with previously treated, unresectable or metastatic HER2-positive biliary tract cancer (BTC) — a significant milestone for patients facing this

How much is due to differences in EGFR/HER3 expressions, ADC targeting/uptake, vs. payload sensitivity?

“ADCs have the potential to supplant chemotherapy & be 1st line treatment for all types of #breastcancer” Dr. Ian Krop #ASCO25 Bonadonna Lecture where he highlighted importance of mentorship & IITs to impact the future of cancer treatment ASCO OncoAlert Smilow Cancer Hospital

Dr. Tony Mok at #ASCO25 with results from HERTHENA-Lung02 of patritumab deruxtecan (HER3-DXd) vs platinum doublet chemo in #EGFR NSCLC post 3G TKI. PFS 5.7 vs 5.4m, HR 0.77 with numeric improvement in intracranial progression HR 0.75.

Dr. Li Zhang at #ASCO25 with Opti-TROP-Lung03 with sacituzumab tirumotecan (Sac-TMT) in EGFR NSCLC post TKI and chemo randomized vs docetaxel. Sac-TMT superior: RR 45% vs 16%, PFS 6.9 vs 2.8m HR 0.30, OS immature but HR 0.49 (HR 0.36 adjusted for crossover). Approved in China.

📢 #ASCO25 | DB-1311/BNT324 B7H3 ADC in Heavily Pretreated CRPC: Phase I/II in CRPC (n=65) shows ORR 27.9%, DCR 95.3%; median rPFS 8.3 m; manageable safety (G≥3 TRAEs 40%). by Andrew Parsonson et al. Full abstract → [shorturl.at/meFe4] ASCO The ASCO Post Journal of Clinical Oncology

Grateful for the opportunity to present DB-1311/BNT324 (a novel B7H3 ADC) a Ph 1/2 study in patients with heavily pretreated CRPC (Abstract #5015) at #ASCO25 🎤 Macquarie University investigators: John Park Dhanusha Sabanathan Howard Gurney Alison Zhang Wei Yen Chan 🧵 1/7

👀👀 in a few hours 👀👀 #ASCO25 #DB09

When you have a packed ASCO room at 7.30 am, you know that a change in practice is coming. #DESTINYBreast09 Sara Tolaney #ASCO25 3 minutes to go

No comments needed 🤩🥳😍 congrats super Sara Tolaney from Dana-Farber and all involved in the #DB09 trial !!!! #ASCO25 OncoAlert ASCO Dana-Farber’s Breast Oncology Center

#ASCO25 #DB09 Sara Tolaney T-DXd + pertuzumab significantly prolonged PFS over THP in first line HER2+ MBC! (40.7 vs 26.9 months) Congrats to everyone involved! Quality data from phase 2 DESTINY-Breast07 perfectly predicted the PFS in the phase 3 DB09 trial (overlap below)!

Telisotuzumab adizutecan (ABBV-400, Temab-A) in #EGFR NSCLC at #ASCO25. This is a cMET ADC like Teliso-V but with a topoisomerase 1 inhibitor. Safety notable for myelosuppression, 7% pneumonitis (1 fatal). RR 63%, DOR 9.8m, PFS 10.9m.

Happening now at #ASCO25: Matteo Carlino, MD (@mattcarlino) from Melanoma Institute Australia, shares results from a melanoma rapid oral abstract session on DYP688 in metastatic uveal #melanoma. ➡️ First ADC-delivered payload to show efficacy in MUM ➡️ Favorable safety/tolerability; most TRAEs

Dr. Isaacs made it clear in her DB09 discussion: we need biomarkers to tailor treatment with T-DXd! At Dana-Farber’s Breast Oncology Center, we’re committed to develop them. With the help of terrific partners, we tested HER2DX & RPPA in a pilot of 40 pts. Intriguing results, working on validation.